LINK: https://bswhealth.webex.com/bswhealth/j.php?MTID=m3ec16638ea3c28003363a7a75733813f 

OBJECTIVES: Upon completion of this activity, the participant should be able to: (1) Review epidemiology, etiology, clinical manifestation and management plan on sarcoidosis. (2) Special focus on pulmonary sarcoidosis. (3) Emerging treatments on sarcoidosis.

FACULTY DISCLOSURE: Habtamu Belete, MD, has no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

PLANNER DISCLOSURE:  Susan Mathai, MD, is a consultant for Natera, Inc, Mount Sinai School of Medicine as an independent contractor, CU Innovations and Geven P15.as a patent Beneficiary and  Cumberland; Foresee; Department of Defense; NIH as a site principal investigator and clinical trial and research study.  Adam Hayek, DO has disclosed he is a researcher for Foresee Pharmaceuticals, Co., Ltd, Jansen-Sirukumab, Mesoblast Inc., Regeneron, and Kinevant Sciences GmbHand.  Ginger Tsai-Nguyen, MD, has no relevant financial relationship(s) to disclose with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships have been mitigated.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information, please contact Alejandro Lopez at Alejandro.CalderonLopez@BSWHealth.org